Identification of BRCA1/2 Founder Mutations in Southern Chinese Breast Cancer Patients Using Gene Sequencing and High Resolution DNA Melting Analysis

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Kwong, Ava ^a,b,c,d   Ng, Enders Kai On ^a,b   Wong, Chris Lei Po ^b,c   Law, Fian Bic Fai ^b,c   Au, Tommy ^b   Wong, Hong Nei ^a   Kurian, Allison W ^d   West, Dee W ^d   Ford, James M ^d   Ma, Edmond Siu Kwan ^b,c  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b HONG KONG SANATORIUM AND HOSPITAL   (Hong Kong)

^c Hong Kong Hereditary Breast Cancer Family Registry ^*  (Hong Kong)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BRCA2 GENE; BREAST CANCER; CANCER GENETICS; CANCER REGISTRY; CANCER RISK; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; EXON; FAMILIAL CANCER; FEMALE; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENE SEQUENCE; GENETIC SCREENING; HAPLOTYPE; HIGH RESOLUTION MELTING ANALYSIS; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; ONCOGENE; POPULATION RESEARCH;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHINA; DNA MUTATIONAL ANALYSIS; FEMALE; FOUNDER EFFECT; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; MUTATION; NUCLEIC ACID DENATURATION; REPRODUCIBILITY OF RESULTS; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 84866068268     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043994     Document Type: Article

References (38)

1. The Hong Kong Cancer Registry (2005) Fast stats for femal breast cancer 2005.
2. Linsley PS, Schelter J, Burchard J, Kibukawa M, Martin MM, et al. (2007) Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Mol Cell Biol 27: 2240-2252.
3. Fackenthal JD, Olopade OI, (2007) Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 7: 937-948.
4. Li CI, Malone KE, Daling JR, (2002) Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev 11: 601-607.
5. Katagiri T, Kasumi F, Yoshimoto M, Nomizu T, Asaishi K, et al. (1998) High proportion of missense mutations of the BRCA1 and BRCA2 genes in Japanese breast cancer families. J Hum Genet 43: 42-48.
6. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, et al. (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378: 789-792.
7. Song CG, Hu Z, Wu J, Luo JM, Shen ZZ, et al. (2006) The prevalence of BRCA1 and BRCA2 mutations in eastern Chinese women with breast cancer. J Cancer Res Clin Oncol 132: 617-626.
8. Zhi X, Szabo C, Chopin S, Suter N, Wang QS, et al. (2002) BRCA1 and BRCA2 sequence variants in Chinese breast cancer families. Hum Mutat 20: 474.
9. Hu Z, Wu J, Liu CH, Lu JS, Luo JM, et al. (2003) The analysis of BRCA1 mutations in eastern Chinese patients with early onset breast cancer and affected relatives. Hum Mutat 22: 104.
10. Sng JH, Chang J, Feroze F, Rahman N, Tan W, et al. (2000) The prevalence of BRCA1 mutations in Chinese patients with early onset breast cancer and affected relatives. Br J Cancer 82: 538-542.
11. Tang NL, Choy KW, Pang CP, Yeo W, Johnson PJ, (2001) Prevalence of breast cancer predisposition gene mutations in Chinese women and guidelines for genetic testing. Clin Chim Acta 313: 179-185.
12. Li WF, Hu Z, Rao NY, Song CG, Zhang B, et al. (2007) The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat.
13. Chen W, Pan K, Ouyang T, Li J, Wang T, et al. (2008) BRCA1 germline mutations and tumor characteristics in Chinese women with familial or early-onset breast cancer. Breast Cancer Res Treat.
14. HK Census (2006) "HK Census." Statistical Table.
15. Hesketh T, Lu L, Xing ZW, (2005) The effect of China's one-child family policy after 25 years. N Engl J Med 353: 1171-1176.
16. Kwong A, Wong LP, Wong HN, Law FB, Ng EK, et al. (2009) A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer. Breast Cancer Res Treat 117: 683-686.
17. Kwong A, Wong LP, Wong HN, Law FB, Ng EK, et al. (2009) Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer. Hugo J 3: 63-76.
18. Kwong A, Ng EK, Law FB, Wong LP, To MY, et al. (2010) High-resolution melting analysis for rapid screening of BRCA2 founder mutations in Southern Chinese breast cancer patients. Breast Cancer Res Treat.
19. Anglian Breast Cancer Study Group (2000) Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 83: 1301-1308.
20. Liede A, Narod SA, (2002) Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2. Hum Mutat 20: 413-424.
21. Inoue R, Ushijima T, Fukutomi T, Fukami A, Sugimura H, et al. (1997) BRCA2 germline mutations in Japanese breast cancer families. Int J Cancer 74: 199-204.
22. Fukutomi T, Ushijima T, Inoue R, Akashi-Tanaka S, Nanasawa T, et al. (1997) BRCA1 and BRCA2 Germline Mutations in Japanese with Hereditary Breast Cancer Families. Breast Cancer 4: 256-258.
23. Choi DH, Lee MH, Bale AE, Carter D, Haffty BG, (2004) Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients. J Clin Oncol 22: 1638-1645.
24. Kurian AW, Gong GD, Chun NM, Mills MA, Staton AD, et al. (2008) Performance of BRCA1/2 Mutation Prediction Models in Asian Americans. J Clin Oncol.
25. Zhou YZ, Sun Q, Lin SQ, Wang J, Liu B, et al. (2004) [Germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in China Han people]. Zhonghua Yi Xue Za Zhi 84: 294-298.
26. Ho GH, Phang BH, Ng IS, Law HY, Soo KC, et al. (2000) Novel germline BRCA1 mutations detected in women in singapore who developed breast carcinoma before the age of 36 years. Cancer 89: 811-816.
27. Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, et al. (2005) Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. Jama 294: 1925-1933.
28. De Leon Matsuda ML, Liede A, Kwan E, Mapua CA, Cutiongco EM, et al. (2002) BRCA1 and BRCA2 mutations among breast cancer patients from the Philippines. Int J Cancer 98: 596-603.
29. Ikeda N, Miyoshi Y, Yoneda K, Shiba E, Sekihara Y, et al. (2001) Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families. Int J Cancer 91: 83-88.
30. Sekine M, Nagata H, Tsuji S, Hirai Y, Fujimoto S, et al. (2001) Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese population. Clin Cancer Res 7: 3144-3150.
31. Torres D, Rashid MU, Gil F, Umana A, Ramelli G, et al. (2007) High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia. Breast Cancer Res Treat 103: 225-232.
32. Tang NL, Pang CP, Yeo W, Choy KW, Lam PK, et al. (1999) Prevalence of mutations in the BRCA1 gene among Chinese patients with breast cancer. J Natl Cancer Inst 91: 882-885.
33. Khoo US, Chan KY, Cheung AN, Xue WC, Shen DH, et al. (2002) Recurrent BRCA1 and BRCA2 germline mutations in ovarian cancer: a founder mutation of BRCA1 identified in the Chinese population. Hum Mutat 19: 307-308.
34. Lee AS, Ho GH, Oh PC, Balram C, Ooi LL, et al. (2003) Founder mutation in the BRCA1 gene in Malay breast cancer patients from Singapore. Hum Mutat 22: 178.
35. Han SA, Park SK, Ahn SH, Lee MH, Noh DY, et al. (2011) The Korean Hereditary Breast Cancer (KOHBRA) study: protocols and interim report. Clin Oncol (R Coll Radiol) 23: 434-441.
36. Li WF, Hu Z, Rao NY, Song CG, Zhang B, et al. (2008) The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat 110: 99-109.
37. Chou LS, Lyon E, Wittwer CT, (2005) A comparison of high-resolution melting analysis with denaturing high-performance liquid chromatography for mutation scanning: cystic fibrosis transmembrane conductance regulator gene as a model. Am J Clin Pathol 124: 330-338.
38. van der Stoep N, van Paridon CD, Janssens T, Krenkova P, Stambergova A, et al. (2009) Diagnostic guidelines for high-resolution melting curve (HRM) analysis: an interlaboratory validation of BRCA1 mutation scanning using the 96-well LightScanner. Hum Mutat 30: 899-909.